CBL-514 Shows Lower Visceral Fat in a Small Trial Subset

From subcutaneous-fat trials to a 41-person visceral-fat analysis

Two phase 2 trials of injected CBL-514, involving 107 and 173 participants, reportedly found reductions in subcutaneous fat, the fat just beneath the skin, in most volunteers.

In a later analysis of 41 participants, those given CBL-514 for up to 12 weeks had an average 12.01% reduction in visceral fat, which is stored around organs, while the placebo group averaged a 5.68% increase four weeks after its final injection. In rats, combining CBL-514 with tirzepatide was also associated with less weight regain after tirzepatide was stopped.

The supplied evidence does not establish that CBL-514 prevents weight regain after GLP-1 treatment in people. The evidence on that question so far comes from animal testing.

Early trial results presented for CBL-514 add a small placebo comparison suggesting lower visceral fat, while rat experiments raise—but do not establish in people—the possibility of less weight regain after tirzepatide is stopped.

Durability and safety require larger longer trials

CBL-514 is being studied as a treatment that triggers apoptosis—programmed cell death—in fat cells rather than simply shrinking them. The early findings point to a possible effect on visceral fat, but larger and longer human trials are needed to assess durability, health effects, and safety.